Lindis Blood Care, a Hennigsdorf, Germany-based medical device company, raised an undisclosed amount in funding.
The round was eldby Brandenburg Kapital. High-Tech Gründerfonds, existing and new private investors as well as the founders, Dr. Franzpeter Bracht and Dr. Horst Lindhofer, also participated.
The company intends to use the funds to prepare for the anticipated approval of the medical device (CE Mark) and product launch in Europe.
Lindis Blood Care is a medical technology company developing CATUVAB®, a medical device that offers a new approach designed to be a safe and cost-effective way to remove tumor cells from autologous blood during high blood loss surgeries. Its mechanism of action is physical and does not involve pharmacological, immunological, or metabolic action. The approach can easily be integrated into existing clinical practice and represents a cost-effective method compared to fully burdened allogeneic blood transfusions and the treatment-related costs due to severe side effects associated with such transfusions.
They are now focusing our efforts on concluding the processes to receive CE Mark in Europe and FDA marketing approval in the US as well as preparing for market launch.
FinSMEs
13/12/2024